恶性临终血浆ALB及Fib水平规律相关性

:未知

   :恶性临终前血浆白(ALB),原(Fib)水平的与的关系。:132例恶性临终前1个月内和1~3个月内的血浆ALB,Fib值,并对值。:恶性临终前1个月内血浆ALB,Fib值1~3个月内值,由学意义(P<0.01);及消化系统中,血浆ALB值有学意义(P<0.05);系,,癌值呈下降趋势,但无学意义(P>0.05)。消化系统及癌中,临终前1个月内血浆Fib值下降,有学意义(P<0.05),,系,中血浆Fib值下降趋势,但无学意义(P>0.05)。血浆ALB和Fib水平与和年龄无关(P>0.05),且血浆ALB和Fib之间不存在相关性(P>0.05)。:血浆ALB及Fib情况恶性临终前的。
  关键词 血浆白;原;恶性;临终;
  分类号  R73    文献标识码  A    编号  1607-0323(2020)07-0307-03
  CHANGES AND CORRELATION OF PLASMA ALB AND FIB LEVELS IN TERMINAL PATIENTS WITH MALIGNANT TUMORS Cai Tengteng,Bu Yuqing?et al.Hebei General Hospital。Shijiazhuang  050051,China
  Abstract  Objective To analyze the relationship between the level of plasma albumin (ALB) and fibrinogen (Fib) and prognosis in patients with malignant tumors before dying. Methods The plasma ALB and Fib values of 128 patients with malignant tumors were collected within 1 month and 07-03 months before dying, and statistical analysis was performed on the two values. Results The detection values of plasma ALB and Fib in patients with malignant tumors were lower than those in 07-03 months before dying (P<0.01). In lung cancer and digestive tract malignant tumors, the difference of plasma ALB measurements was statistically significant (P<0.05); The urinary tumor, gynecological tumor。 and breast cancer showed a downward trend, but there was no statistical difference (P>0.05). In digestive tract malignancies and breast cancer, the plasma Fib test value decreased significantly within 1 month before the end of dying (P<0.05).The two levels of plasma Fib in lung cancer, urinary tumor and gynecological tumor showed a downward trend, but there was no statistical difference (P>0.05).Plasma ALB and Fib levels were not associated with gender and age (P>0.05). Besides, there was no correlation between plasma ALB and Fib (P>0.05). Conclusion Changes in plasma ALB and Fib can be used as indicators of prognosis in patients with malignant tumors before dying.
  Key words  Albumin;Fibrinogen;Malignancy;Death;Prognosis
  范圍内恶性的死亡率,2018年中国癌症死亡约占癌症死亡的 30%[1]。恶性诊断技术及方式的进展,恶性的也越来越被。的及恶性的[07-03],血浆白(Albumin, ALB)及原(Fibrinogen, Fib)人体及,近年来ALB及Fib被应恶性的[07-03]。目前关于恶性临终血清ALB及Fib水平情况与关系的,且大部分某种特定的恶性。本对132例恶性临终临终前1~3个月血清中ALB及Fib值与临终前1个月ALB及Fib值的水平回顾性,恶性临终ALB及Fib水平对的意义。   1 对象与
  1.1 对象
  选取2016年8月至2019年8月在河北省人民医院科并死亡的诊断为恶性132例为对象,其中男79例。女53例;年龄25~93岁,中位年龄67岁;恶性39例,消化系统50例,系恶性13例,恶性7例,恶性15例,其他恶性8例。资料临终前1个月内及1~3个月的及。
  1.2
  采外周静脉血2mL,枸橼真空抗凝管内,混匀,本院室,离心 10 min,血浆。严格书ALB及Fib。ALB采用曼库尔特系统白盒(溴绿法);Fib采用SIEMENS原(法)。资料及病检,资料,包括:年龄,,病理等。
  1.3 学
  采用SPSS25.0,资料符合正态分布以“均数±差”,两组均数比较采用t检验;不符合正态分布的以“中位数(位数)”,中位数比较采取Wilcoxon秩检验;两组关系采用Spearman相关;P<0.05为有学意义。
  2
  2.1临终前血浆ALB,Fib
  恶性临终期1个月内血浆ALB及Fib值较1~3个月时,有学意义(P<0.05),见表1。
  2.2 恶性临终前血浆ALB,Fib
  将组,消化系统组,系组,组及癌组。组及消化系统组血浆ALB临终前1个月内下降(P<0.05),其他各组血浆ALB值下降趋势,但无学意义(P>0.05);消化系统组及癌组血浆Fib临终前1个月内下降(P<0.05),而有下降趋势,但无学意义(P>0.05),见表2。
  2.3 恶性临终前血浆ALB,Fib程度比较
  以血浆ALB,Fib “临终前1~3个月值-临终前1个月值”程度的,显示,间血浆ALB,Fib程度学意义(P >0.05),见表3。
  2.4 年龄恶性临终前血浆ALB,Fib程度比较
  年龄两组,比较年龄恶性临终前血浆ALB,Fib程度。显示,恶性临终前血浆ALB,Fib程度年龄学意义(P>0.05),见表4。
  2.5 恶性临终前血浆ALB与Fib相关性
  恶性临终前1个月内及07-03个月内血浆ALB与Fib之相关性。显示,观察点血浆ALB与Fib相关性(P>0.05),见表5。
  3讨论
  恶性的,质增强,而能力,的高容易导致[6]。又导致 能力下降,恶性的。由于很促凝活性,恶性往往伴有和纤溶系统的,体内将[07-03]。体内的高凝导致血栓的[12],也DIC[13],从而恶性的。本通过恶性临终前血浆ALB及Fib值水平,为恶性临终的。
  显示恶性率在40%~80%之间,风险率为39%~68%[14],上血液学来[15],在血液学中,ALB水平是最常应。血浆ALB,小有机物和等物,并且血浆渗透压,然而血浆ALB水平会体内环境,导致。多项表明血浆ALB与相关[07-03]。目前仅特定血浆ALB单次与预关系[07-03]。通过对恶性临终前血浆ALB水平,能够更直接的表明血浆ALB水平与病情之关系。本通过对132例恶性临终前1~3个月血浆ALB值1个月内值比较,证明了恶性临终期血浆ALB水平随病情进展而下降,恶性临终前1~3个月ALB水平1个月内水平,恶性病情的进展伴,血浆ALB水平与恶性临终期相关。对恶性亚组,和消化系统终末期血浆ALB水平下降;系统,癌,临终期血浆ALB趋势,但无学,是样本量导致。,本了和女性之间血浆ALB值的情况,发现血浆ALB的水平与和年龄无关。本显示的恶性临终前ALB较前下降,临终期恶性的。
  表明[07-03],恶性与之间存在着紧密。Fib又被称为因子I,主肝,Fib与,更与血小板,微血栓,,增强及能力。目前[07-03]证实Fib水平与恶性的存在正相关。本比较132例临终前Fib值水平,显示临终前1个月内较1~3个月Fib。与未在临终期,而临终期,Fib能力下降,导致Fib水平下降。也由于恶性釋放促凝物质,使高凝,容易DIC[07-03]。有显示,的因子与 DIC 的发展存在密切[30]。DIC使体内因子被,Fib水平。有表明晚期DIC率占24%~34%[31],恶性DIC死亡率高达85.1%[32]。亚组显示消化系统及癌终末期血浆Fib水平下降;,系统,临终期血浆Fib存在下降趋势,但学意义。本了和年龄之间血浆Fib值的情况,未发现血浆Fib的水平与和年龄相关性。有显示阶段血浆ALB与Fib之间存在相关性[33],未临终期。而本显示血浆ALB与Fib两者之间并无相关性。本显示恶性临终前Fib下降,的。   綜上所述,通过对恶性死亡血浆ALB,Fib的,的病情,血浆ALB及Fib水平与病情及相关性,对终末期恶性。
  4参考文献
  [1] 王宁, , , 等. 2018癌症[J]. 电子,5(01):07-03.
  [2]Mantzorou M, Koutelidakis A, et al. Clinical Value of Nutritional Status in Cancer: What is its Impact and how it Affects Disease Progression and Prognosis?[J]. Nutr Cancer,69(8):1107-0376.
  [3] Agnelli G, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer[J]. N Engl J Med,366(7):607-039.
  [4] Agnelli G, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer[J]. N Engl J Med,366(7):607-039.
  [5] Ravasco P, Monteiro-Grillo I。 Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy[J]. Am J Clin Nutr。96(6):1307-0353.
  [6] Egenvall M, Morner M。 Martling A, et al. Prediction of outcome after curative surgery for colorectal cancer: preoperative  haemoglobin, C-reactive protein and albumin[J]. Colorectal Dis, 2018?20(1):07-03.
  [7] Vazeille C, Durand J P, et al. Relation between hypermetabolism, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy[J]. Am J Clin Nutr?105(5):1107-0347.
  [8] Zhang Y, Xiao G. Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis[J]. Cancer Manag Res。11:3307-0393.
  [9] , 张卫宁, , 等. [J]. 血栓与学,25(01):07-03.
  [10] 吐尔逊江·艾力, 赵盼盼? . 癌与生物学的关系[J]. 中国医药,10(11):07-03.
  [11] Beer J H, Vogt A, et al. Coagulation markers predict survival in cancer patients[J]. Thromb Haemost,88(5):707-039.
  [12] Lyman G H, Khorana A A. Cancer, clots and consensus: new understanding of an old problem[J]. J Clin Oncol,27(29):4807-0326.
  [13], 高清平. 性内的[J]. 急危重症, 2016。22(03):107-038.
  [14] Orrevall Y, Tishelman C, et al. Nutritional support and risk status among cancer patients in palliative home care services[J]. Support Care Cancer,17(2):107-031.
  [15] Correira P M, et al. Scored Patient-Generated Subjective Global Assessment? albumin and transferrin for nutritional assessment of gastrostomy fed head or neck cancer patients[J]. Nutr Hosp, 2014?29(2):407-036.   [16] Shimura T, Toiyama Y, Hiro J, et al. Monitoring perioperative serum albumin can identify anastomotic leakage in colorectal cancer patients with curative intent[J]. Asian J Surg, 2018?41(1):07-03.
  [17]Yamamoto M, Saito H。 et al. Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer[J]. Anticancer Res,39(2):1007-0390.
  [18] Wu M T, Chen S L。 et al. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma[J]. BMC Cancer,19(1):538.
  [19] Long Z Q, et al. Prognostic impact of the pretreatment albumin to alkaline phosphatase ratio for nonmetastatic breast cancer patients[J]. Cancer Manag Res。11:4807-0314.
  [20] Liu D Q, Li F F, Jia W H. Cumulative scores based on plasma D-dimer and serum albumin levels predict survival in esophageal squamous cell carcinoma patients treated with transthoracic esophagectomy[J]. Chin J Cancer, 2016。35:11.
  [21] Onate Ocana L F, Aiello Crocifoglio V, Gallardo Rincon D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma[J]. Ann Surg Oncol, 2007,14(2):307-039.
  [22] Palumbo J S, Kombrinck K W, Drew A F, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells[J]. Blood,96(10):3307-0309.
  [23] Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity[J]. Cancer Sci,100(5):807-035.
  [24] Perisanidis C, Psyrri A? et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors:  A systematic review and meta-analysis[J]. Cancer Treat Rev,41(10):907-030.
  [25] Sheng L, et al. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer[J]. Int J Cancer,133(11):2707-0325.
  [26] Tas F, Kilic L, et al. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer。23(2):207-031.
  [27] Son H J, Park J W, Chang H J, et al. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer[J]. Ann Surg Oncol,20(9):2907-0313.
  [28] Iba T, Di Nisio M, Thachil J, et al. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity[J]. Crit Care。 2016。20:287.
   [29] Levi M. Disseminated Intravascular Coagulation in Cancer: An Update[J]. Semin Thromb Hemost,45(4):307-037.
  [30] Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer[J]. Thromb Res, 2001,102(6):V215-V224.
  [31] 張之南,. 血液病诊断及疗效[M]. : 科学出版社, 2018.
  [32] 陈慧敏, , 王. 恶性并发性内因素及对的[J]. 中国与, 2018?25(12):1407-0301.
  [33] 李芳芳, 闫斌斌, 史笑梅, 等. 阶段高凝相关的及意义[J]. 与,25(02):107-039.
  [07-03]
  :河北省重点与生物医药专项(编号:18277718D)
  单位:066000 河北省石家庄市,河北省人民医院
  *
:https://www.acadtouch.com/6/view-15198210.htm

相关

服务推荐


Baidu